The Institute of Medical Sciences and Sum Hospital (IMS and SUM Hospital) is the medical school of the Siksha 'O' Anusandhan in Bhubaneswar, Odisha, India. This institute gained permission in 2007 from Medical Council of India to start the MBBS courses in medical stream.It provides undergraduate courses in medicine and dentistry, and postgraduate courses in non-clinical departments. It has begun providing post graduation in clinical subjects like surgery and anesthesia.It provides speciality services including Neurosurgery, pediatric surgery, plastic surgery, urology, oncological surgery, surgical gastroenterology, endocrinology, rheumatology,cardiology, neurology, nephrology, plastic surgery and neo-natalogy.
Provision of invasive mechanical ventilation (IMV) in the neonatal intensive care has seen a steady rise in low-esource settings (LRS). However, outcomes among those exposed to IMV remain under-reported, with the current evidence base being restricted to single-centre observational studies, thus limiting comparative analyses and effective healthcare planning. This study aims to estimate the pooled proportion of mortality and morbidity among neonates exposed to IMV in low-resource settings. Medline, Embase, and CENTRAL were searched until 22 August 2025. Randomised and non-randomised studies were included. Two reviewers, blinded to each other, extracted data independently. Proportion-based meta-analyses using random-effects model were performed. Risk of bias was assessed using ROBINS-E, and evidence-certainty was evaluated using the GRADE approach. One hundred of 117 studies were included, with most conducted in South Asia. In-hospital mortality was reported in 68 studies (7193 neonates), with a pooled estimate of 45
BACKGROUND:Screening for latent tuberculosis (LTB) before initiating advanced therapy for inflammatory bowel disease (IBD) helps reduce the risk of tuberculosis (TB) development. However, there is limited data on screening practices from TB-endemic regions. AIM:To study the practices of screening for LTB and study the incidence of TB in patients with IBD on biological and small molecule inhibitors. METHODS:This retrospective multicentre study analyzed LTB screening practices in IBD patients starting advanced therapies between 2018 and 2022. We included patients who were initiated on biologics (infliximab, adalimumab, vedolizumab) or small molecule inhibitors (tofacitinib). We assessed compliance with LTB screening methods, including the tuberculin skin test, interferon-gamma release assay (IGRA), chest X-ray, and computed tomography chest, both at initiation and annually. We also evaluated the incidence of active TB and its predictors. RESULTS:Of 378 patients (mean age: 36.9 ± 14.9 years, males: 56.9%), 158 (41.8%) and 216 (57.1%) had ulcerative colitis and Crohn's disease, respectively. Advanced therapy used were anti-tumor necrosis factor in 309 (81.74%), tofacitinib in 41 (10.84%) and vedolizumab in 28 (7.40%). Standard screening and diligent screening strategy was employed in 59% and 33% of patients, respectively. Compliance with tuberculin skin test and IGRA was noted in 261 (69.04%) and 298 (78.83%) patients, respectively. Chest X-Ray and computed tomography chest were performed in 300 (79.36%) and 242 (64.02%), respectively. Annual screening in those on advanced therapy for > 1 year was performed in 27.2% (50/184). Active TB developed in 17 (4.49%); 15 (88.23%) were on anti-tumor necrosis factor. LTB was detected in 40 (10.72%), with most diagnosed on the basis of IGRA (21/40, 52.50%). Among 17 patients who developed active TB, LTB screen was negative in 12 (70.58%). CONCLUSION:Standard screening practices for LTB, prior to starting advanced therapy, remain suboptimal (< 60%) in India despite high TB endemicity.
Esophageal/gastric varices (EV), especially clinically significant varices (CSV), represent life-threatening complications of pediatric portal hypertension (PH), necessitating timely detection. While esophagogastroduodenoscopy (EGD) remains the gold standard, its invasive nature and requirement for sedation in children highlight the need for reliable non-invasive alternatives for screening and risk stratification. Splenic stiffness measurement (SSM) has emerged as a potential tool. This systematic review and meta-analysis aimed to evaluate diagnostic accuracy of SSM for detecting EV and CSV in pediatric PH. A comprehensive search of PubMed, Scopus and Embase was performed up to January 2025. Studies assessing SSM via elastography in pediatric (< 18 years) PH, with EGD as reference standard for EV/CSV detection, were included. Data was synthesized using hierarchical summary receiver operating characteristic (HSROC) model to estimate pooled sensitivity, specificity, diagnostic odds ratio (DOR) and area under the receiver operating characteristic curve (AUROC). Risk of bias was evaluated using Quality Assessment of Studies of Diagnostic Accuracy (QUADAS-2) tool. Ten studies encompassing 618 patients were analyzed. For EV prediction (3 studies, n = 158), pooled sensitivity, specificity and DOR were 0.80 (95
BACKGROUND:Several countries are using fractionated or limited-dose regimens of full dose inactivated polio vaccine (IPV) in infants in addition to oral poliovirus vaccine (OPV), due to procurement cost of IPV and delivery challenges for its campaign use. An adjuvanted dose-sparing IPV (ds-IPV) with around a one-fourth antigen content of the full dose of IPV was developed in India. A non-inferiority trial was conducted to compare the immune response of ds-IPV with IPV in infants. METHODS:A phase 2/3, double-blind, randomised controlled trial was conducted at nine tertiary care hospitals in India. Healthy infants aged 6-8 weeks, who received a birth dose of bivalent OPV were enrolled. Participants with fever or acute infection, and previous receipt or plan to receive any other poliovirus-containing vaccines were excluded. Infants were randomly assigned (1:1; block randomisation managed through an interactive web response system) to receive either ds-IPV or IPV in a three-dose regimen-a single dose of 0·5 mL administered by intramuscular route at age 6 weeks, 10 weeks, and 14 weeks. The vaccine syringes were masked with an opaque peel before administration to maintain masking. All participants were concomitantly administered oral rotavirus vaccine, and injectable DTwP-HB-Hib and pneumococcal conjugate vaccine in the contralateral thigh by the intramuscular route. Blood samples were collected at baseline before the first dose and at 28 days after the third dose for measuring the neutralising antibodies against each poliovirus serotype using microneutralisation assay. The site staff evaluating the study outcomes, participants' parents, and the laboratory personnel were masked to the vaccine allocations. The primary outcome of type-specific percentage seroconversion at 28 days after the third dose of ds-IPV or IPV (non-inferiority margin ≥10%) and secondary outcomes of type-specific geometric mean titres and percentage seroprotection (titre ≥8) were assessed in the per-protocol population as the primary population and the full analysis population as the supportive population. Secondary outcomes on safety evaluation included immediate, solicited, unsolicited, and serious adverse events. This study is registered with the Clinical Trials Registry of India (CTRI/2022/05/042363), and is complete. FINDINGS:Between May 23, 2022, and April 13, 2024, of the 658 participants screened, 648 were eligible and randomly assigned to ds-IPV (n=324) or IPV (n=324). Consent was withdrawn for five participants after randomisation; thus, a total of 643 infants received ds-IPV (n=323) or IPV (n=320). The seroconversion rates for type 1 poliovirus in the ds-IPV and IPV groups were 283 (94·7% [95% CI 91·5 to 96·9]) of 299 participants and 270 (92·8% [89·2 to 95·5]) of 291 participants, respectively, with a difference of 1·9 (95% CI -2·1 to 5·8). The seroconversion rates for type 2 poliovirus in the ds-IPV and IPV groups were 287 (96·3% [93·5 to 98·1]) of 298 participants and 284 (97·9% [95·6 to 99·2]) of 290 participants, respectively, with a difference of -1·6 (-4·7 to 1·5). The seroconversion rates for type 3 poliovirus in the ds-IPV and IPV groups were 291 (97·3% [94·8 to 98·8]) of 299 participants and 288 (99·0% [97·0 to 99·8]) of 291 participants, respectively, with a difference of -1·6 (-3·8 to 0·5). Solicited events, including tenderness, redness, swelling, and fever, were very common (≥10%) in both vaccine groups. No causally related serious adverse events were reported. INTERPRETATION:ds-IPV was immunologically non-inferior to IPV and had a similar safety profile. The new adjuvanted IPV could become an alternative option to IPV. The availability of ds-IPV will support a constant supply of IPV for use in poliovirus-naive and exposed target populations. FUNDING:Serum Institute of India.